U.S. poised to issue rule subjecting Chinese biotech licensing deals to additional scrutiny
23 October 2026 · filed under 82dd6b13e46f
The United States is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotechnology companies to additional scrutiny, according to STAT News, published October 22, 2026.
The report, part of STAT’s Pharmalot roundup, indicates the rule would apply to licensing arrangements between U.S. and Chinese biotech firms, though the supplied material does not elaborate on the rule’s mechanics beyond that description.
The same roundup references a separate item concerning Belgium’s refusal to cover Mounjaro, though no further detail on that matter is provided in the supplied summary.
STAT’s Pharmalot column typically aggregates brief items on pharmaceutical and biotech news; this entry falls within that format. The cited material offers a summary-level description of the proposed rule’s subject, outbound licensing deals with Chinese biotech companies, without additional specifics on implementation, scope, or agency involvement.
No further detail from the underlying STAT report is available in the material provided for this bulletin. Readers seeking the full account, including any additional context STAT may have included on either item, should consult the original Pharmalot column directly.